-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★ Nanjing · Big coffee gathered in May2021 nucleic acid drug development forum announced the schedule★ May Nanjing2021 nucleic acid drug development forum is about to open April 20, 2021 / Yimaike news eMedClub News/--CAR- T therapy, that is, chimeric antigen receptor T cell immunotherapy, through genetic modification technology, allows patients’ T cells to express chimeric antigen receptors, making effector T cells more targeted, lethal and durable than conventionally used immunity With high cells, overcoming the tumor's local immunosuppressive microenvironment and breaking the host immune tolerance state, a large number of leukemia and lymphoma patients treated with anti-CD19 or anti-CD22 CAR-T cell therapy relapse due to loss or downregulation of antigen.
In order to solve the escape of tumor antigens and overcome this drug resistance, researchers have developed dual-target CAR-T cells and obtained good data in a number of studies.
Based on these studies, a team of scientists from Lentigen, a subsidiary of Miltenyi Biotec, designed tri-specific duoCAR-T cells that simultaneously target CD19, CD20 and CD22.
DuoCAR-T cell therapy can effectively kill antigen-heterogeneous tumor cells in vitro mixture.
In addition, in the mouse model, the trispecific duoCAR-T cell therapy has also successfully controlled the burden of antigen heterogeneous tumors.
The results of the study were published in Science Translational Medicine.
Scientists designed trispecific duoCAR-T cells using lentiviral vectors encoding two CAR open reading frames.
duoCARs consist of a CAR that is tandem CD19 binder (scFv) and CD20 binder (scFv) connected to another CAR that targets CD22 through a P2A self-cleaving peptide.
The study evaluated a variety of intracellular T cell signaling motif combinations, and the most effective duoCAR structure contained ICOS, OX40 or CD27 costimulatory domains instead of CD28 or 4-1BB.
In in vitro studies, duoCAR-T cells, like single CAR-T cells, lyse target-positive tumor cell lines in a dose-dependent manner.
In an in vivo study, duoCAR-T cells were injected through the tail vein, and the results showed that DuoCAR-T cells can eliminate diffuse CD19+CD20+CD22+Raji and NALM-6 tumor cells in vivo.
The development history of CAR-T As early as 2010, Professor Carl June of the University of Pennsylvania used CAR-T technology to successfully relieve three CD19-positive chemotherapy-ineffective or relapsed leukemia patients for the first time.
The leukemia cells in the body were cleared, and at the same time, The complete remission rate in the treatment of acute lymphoblastic leukemia can reach 90%.
The effect of CAR-T therapy is amazing and exciting, and it has received great attention all over the world.
Subsequently, in the course of more than ten years of development, the US FDA has approved 5 CAR-T cell products.
On August 30, 2017, the FDA approved Novartis’ CAR-T therapy Kymriah (Tisagenlecleucel, tisa-cel) for the market to treat refractory or at least relapsed B-cell acute lymphoblastic leukemia (ALL) after receiving at least second-line treatment.
Since then, the world's first approved CAR-T cell product was born.
In 2018, the US FDA again approved Kymriah's second indication, relapsed or refractory large B-cell lymphoma.
In October 2017, Gilead/Kite's CAR-T product Yescarta (Axicabtagene Ciloleucel, Axi-Cel) was approved by the US FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL).
In July 2020, Gilead/Kite's CAR-T product Tecartus (brexucabtagene autoleucel, formerly known as KTE-X19) was approved by the US FDA for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL).
The press release stated that this is the first CAR-T therapy approved for the treatment of MCL.
This also makes Kite the first company to have multiple approved CAR-T therapies.
In February 2021, Bristol-Myers Squibb (BMS) CAR-T cell product Liso-cel was approved by the US FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
On March 27, 2021, Bristol Myers Squibb and Bluebird Bio jointly announced that the FDA approved the BCMA CAR-T treatment product Abecma (idecabtagene vicleucel) jointly developed by the two parties to be marketed for the treatment of relapsed or refractory multiple myeloma (Multiple myeloma), became the world's first CAR-T therapeutic product targeting BCMA.
However, as the drug resistance mentioned above, CAR-T cells still have certain challenges, such as side effects and off-target effects.
With the efforts of many scientific researchers, I believe that CAR-T can achieve breakthroughs and progress in the future.
Reference materials: 1.
Medical Rubik's Cube "Three-specific CAR-T, the dawn of dawn" 2.
https://stm.
sciencemag.
org/content/13/586/eabc64013.
https://lymphomahub.
com/medical-information /results-from-phase-i-alexander-study-investigating-the-first-car-t-cell-therapy-auto3-plus-pembrolizumab-to-target-both-cd19-and-cd22-in-the-treatment -of-rr-dlbcl is always committed to original news reports such as cutting-edge technology, industry trends, and industry insights of bio-innovative drugs.
The high-end matrix users of all media have reached 160,000+, of which industrial users account for more than 50%.
Research and clinical About 30% of users, and more than 5% of investment institutions.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups.
In order to solve the escape of tumor antigens and overcome this drug resistance, researchers have developed dual-target CAR-T cells and obtained good data in a number of studies.
Based on these studies, a team of scientists from Lentigen, a subsidiary of Miltenyi Biotec, designed tri-specific duoCAR-T cells that simultaneously target CD19, CD20 and CD22.
DuoCAR-T cell therapy can effectively kill antigen-heterogeneous tumor cells in vitro mixture.
In addition, in the mouse model, the trispecific duoCAR-T cell therapy has also successfully controlled the burden of antigen heterogeneous tumors.
The results of the study were published in Science Translational Medicine.
Scientists designed trispecific duoCAR-T cells using lentiviral vectors encoding two CAR open reading frames.
duoCARs consist of a CAR that is tandem CD19 binder (scFv) and CD20 binder (scFv) connected to another CAR that targets CD22 through a P2A self-cleaving peptide.
The study evaluated a variety of intracellular T cell signaling motif combinations, and the most effective duoCAR structure contained ICOS, OX40 or CD27 costimulatory domains instead of CD28 or 4-1BB.
In in vitro studies, duoCAR-T cells, like single CAR-T cells, lyse target-positive tumor cell lines in a dose-dependent manner.
In an in vivo study, duoCAR-T cells were injected through the tail vein, and the results showed that DuoCAR-T cells can eliminate diffuse CD19+CD20+CD22+Raji and NALM-6 tumor cells in vivo.
The development history of CAR-T As early as 2010, Professor Carl June of the University of Pennsylvania used CAR-T technology to successfully relieve three CD19-positive chemotherapy-ineffective or relapsed leukemia patients for the first time.
The leukemia cells in the body were cleared, and at the same time, The complete remission rate in the treatment of acute lymphoblastic leukemia can reach 90%.
The effect of CAR-T therapy is amazing and exciting, and it has received great attention all over the world.
Subsequently, in the course of more than ten years of development, the US FDA has approved 5 CAR-T cell products.
On August 30, 2017, the FDA approved Novartis’ CAR-T therapy Kymriah (Tisagenlecleucel, tisa-cel) for the market to treat refractory or at least relapsed B-cell acute lymphoblastic leukemia (ALL) after receiving at least second-line treatment.
Since then, the world's first approved CAR-T cell product was born.
In 2018, the US FDA again approved Kymriah's second indication, relapsed or refractory large B-cell lymphoma.
In October 2017, Gilead/Kite's CAR-T product Yescarta (Axicabtagene Ciloleucel, Axi-Cel) was approved by the US FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (LBCL).
In July 2020, Gilead/Kite's CAR-T product Tecartus (brexucabtagene autoleucel, formerly known as KTE-X19) was approved by the US FDA for the treatment of adult patients with relapsed/refractory mantle cell lymphoma (MCL).
The press release stated that this is the first CAR-T therapy approved for the treatment of MCL.
This also makes Kite the first company to have multiple approved CAR-T therapies.
In February 2021, Bristol-Myers Squibb (BMS) CAR-T cell product Liso-cel was approved by the US FDA for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
On March 27, 2021, Bristol Myers Squibb and Bluebird Bio jointly announced that the FDA approved the BCMA CAR-T treatment product Abecma (idecabtagene vicleucel) jointly developed by the two parties to be marketed for the treatment of relapsed or refractory multiple myeloma (Multiple myeloma), became the world's first CAR-T therapeutic product targeting BCMA.
However, as the drug resistance mentioned above, CAR-T cells still have certain challenges, such as side effects and off-target effects.
With the efforts of many scientific researchers, I believe that CAR-T can achieve breakthroughs and progress in the future.
Reference materials: 1.
Medical Rubik's Cube "Three-specific CAR-T, the dawn of dawn" 2.
https://stm.
sciencemag.
org/content/13/586/eabc64013.
https://lymphomahub.
com/medical-information /results-from-phase-i-alexander-study-investigating-the-first-car-t-cell-therapy-auto3-plus-pembrolizumab-to-target-both-cd19-and-cd22-in-the-treatment -of-rr-dlbcl is always committed to original news reports such as cutting-edge technology, industry trends, and industry insights of bio-innovative drugs.
The high-end matrix users of all media have reached 160,000+, of which industrial users account for more than 50%.
Research and clinical About 30% of users, and more than 5% of investment institutions.
In order to promote interactive exchanges in industry segments, we have established a number of professional WeChat groups, welcome to scan the QR code to add groups.
